The present invention relates to methods for the identification and characterization of therapeutic candidates for use in the treatment of a disease or condition associated with elevated LDL-C levels involving a rodent, methods for the testing of the efficacy of an antibody specifically binding to proprotein convertase subtilisin/kexin type 9 (PCSK9) involving a rodent, as well as a rodent and its use in the identification or profiling of compounds for modulation of a disease or condition associated with elevated LDL-C levels.
